|Dr. William L. Hunter M.D., Msc, BSc||Pres, CEO, MD & Director||1.34M||N/A||54|
|Ms. Sheila M. Grant MBA||Chief Operating Officer||394k||N/A||N/A|
|Mr. David D. McMasters Esq., J.D.||Gen. Counsel||540.52k||N/A||58|
|Ms. Jennifer Michael Archibald CPA, CA||Chief Bus. Operations Officer||429k||N/A||N/A|
|Mr. Hugues Sachot||CCO||598.17k||N/A||N/A|
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
Cardiome Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.